Aug. 25th, 2021 & PD-L1: The non-randomized open-

Aug. 25th, 2021 & PD-L1:
The non-randomized open-label study included 30 patients who were treated with leronlimab at a weekly dose of 350 mg until experiencing disease progression or intolerable toxicity.

Eligible patients were required to have histologically confirmed, locally recurrent or metastatic TNBC and be CCR5-positive by immunohistochemistry testing. Patients needed to either provide tissue from a new core or excisional biopsy or tumor lesion in order to enroll. Disease needed to be measurable by RECIST v1.1 criteria with an ECOG performance status of 0 or 1.

Notably, those with HER2 overexpression or amplification, estrogen receptor– or progesterone receptor–expressing tumors, who are PD-L1–positive and eligible for atezolizumab (Tecentriq), or were part of another study featuring an investigational agent were not eligible to enroll on the trial
___

So they were 1st testing for 350mg/PD-L1 effect.
Later confirmed 525/700mg was best to make PD-L1 overexpress --- "expose its existence" for ICI.

So everything has been intentional result(s)
No surprises per say post legal settlement

We had multiple trials target compiling PD-L1

Now most likely the CRC poster did the same --- dose escalated, ICI added & survivors increased.

GMB will show a 3rd success story when dose increased & ICI added